Search Results - "Dorofeyev, Andrey"

Evaluation of the Impact of Some Single-Nucleotide Gene Polymorphisms on the Development of Adenomatous Polyps of the Colon in Patients with Irritable Bowel Syndrome by Kyrian, Olena, Dorofeyev, Andrey, Derkach, Igor, Zhigal, Yulia

“…The number of cases of irritable bowel syndrome is growing worldwide, in which adenomatous polyps can develop as a result of microinflammation of the colonic…”
Get full text

Budesonide Suppositories Are Effective and Safe for Treating Acute Ulcerative Proctitis by Kruis, Wolfgang, Neshta, Viacheslav, Pesegova, Marina, Alekseeva, Olga, Andreev, Pavel, Datsenko, Oleksii, Levchenko, Olena, Abdulkhakov, Sayar, Lozynskyy, Yuriy, Mostovoy, Yuriy, Soloviev, Konstantin, Dorofeyev, Andrey E., Vieth, Michael, Stiess, Michael, Greinwald, Roland, Mohrbacher, Ralf, Siegmund, Britta

“…Although proctitis is the most limited form of ulcerative colitis, it causes unpleasant symptoms. Topical mesalamine, the standard treatment, is not always…”
Get full text

Clinical trial: A novel high‐dose 1 g mesalamine suppository (salofalk) once daily is as efficacious as a 500‐mg suppository thrice daily in active ulcerative proctitis by Andus, Tilo, Kocjan, Andreas, Müser, Moritz, Baranovsky, Andrey, Mikhailova, Tatyana L., Zvyagintseva, Tatyana D., Dorofeyev, Andrey E., Lozynskyy, Yurii S., Cascorbi, Ingolf, Stolte, Manfred, Vieth, Michael, Dilger, Karin, Mohrbacher, Ralf, Greinwald, Roland

“…Background: Mesalamine suppositories are first‐line therapy in active ulcerative proctitis; the standard regime still recommends multiple doses per day. The…”
Get full text

Sa1794 Recurrence Rate After Uncomplicated Diverticulitis and Evaluation of Risk Factors for Relapses After an Attack of Uncomplicated Diverticulitis by Kruis, Wolfgang, Mohrbacher, Ralf, Greinwald, Roland, Banai, János, Bunganic, Ivan, Dorofeyev, Andrey E, Kardalinos, Vassilios, Spiller, Robin C

Get full text

3g mesalazine granules are superior to 9mg budesonide for achieving remission in active ulcerative colitis: A double-blind, double-dummy, randomised trial by Gross, Volker, Bunganic, Ivan, Belousova, Elena A., Mikhailova, Tatyana L., Kupcinskas, Limas, Kiudelis, Gediminas, Tulassay, Zsolt, Gabalec, Libor, Dorofeyev, Andrey E., Derova, Jelena, Dilger, Karin, Greinwald, Roland, Mueller, Ralph

“…Budesonide may be an effective therapy for mild-to-moderately active ulcerative colitis (UC). This study aimed to demonstrate non-inferiority for oral 9mg…”
Get full text

Sa1217 Once Daily Dosing of 9mg Budesonide (Budenofalk®) Is Therapeutic Equivalent to a Three-Times Daily Dosing of 3mg Budesonide for the Treatment of Active Crohn's Disease: A Randomized, Double-Blind, Double-Dummy, Multicenter Phase III Study by Dignass, Axel U, Stoynov, Simeon, Dorofeyev, Andrey E, Grigorieva, Galina A, Tomsova, Eva, Altorjay, István, Tuculanu, Daniel, Bunganic, Ivan, Pokrotnieks, Juris, Kupcinskas, Limas, Greinwald, Roland, Mueller, Ralph

Get full text

1052 Daily Mesalamine Fails to Prevent Recurrent Diverticulitis in a Large Placebo Controlled Multicenter Trial by Kruis, Wolfgang, Kardalinos, Vassilios, Curtin, Austin, Dorofeyev, Andrey E, Zakko, Salam F, Wölkner, Jens, Alonso, Manuel M. Diez, Peeters, Harald, Koutroubakis, Ioannis E, Talley, Nicholas J, Dilger, Karin, Mohrbacher, Ralf, Greinwald, Roland

Get full text

Once versus three times daily dosing of oral budesonide for active Crohn's disease: A double-blind, double-dummy, randomised trial by Dignass, Axel, Stoynov, Simeon, Dorofeyev, Andrey E., Grigorieva, Galina A., Tomsová, Eva, Altorjay, István, Tuculanu, Daniel, Bunganič, Ivan, Pokrotnieks, Juris, Kupčinskas, Limas, Dilger, Karin, Greinwald, Roland, Mueller, Ralph

“…Oral budesonide 9mg/day represents first-line treatment of mild-to-moderately active ileocolonic Crohn's disease. However, there is no precise recommendation…”
Get full text

Clinical, endoscopical and morphological efficacy of mesalazine in patients with irritable bowel syndrome by Dorofeyev, Andrey E, Kiriyan, Elena A, Vasilenko, Inna V, Rassokhina, Olga A, Elin, Andrey F

“…The aim of this study was to analyze the clinical efficacy and cytomorphologic changes of colon mucosa following the treatment of patients suffering from…”
Get full text

Gastrointestinal health: changes of intestinal mucosa and microbiota in patients with ulcerative colitis and irritable bowel syndrome from PM2.5-polluted regions of Ukraine by Dorofeyev, Andrey, Dorofeyeva, Anna, Borysov, Arsenii, Tolstanova, Ganna, Borisova, Tatiana

“…Here, clinical studies of patients were conducted to assess changes in patients with ulcerative colitis (UC) and irritable bowel syndrome (IBS) associated with…”
Get full text

Biochemical and Heart Adaptations to Physical Training and Supplementation With Amino Acids by Dorofeyeva, Elena E., Dorofeyev, Andrey E.

“…Dorofeyeva, E.E., and A.E. Dorofeyev. Biochemical and heart adaptations to physical training and supplementation with amino acids. J. Strength Cond. Res…”
Get full text

BIOCHEMICAL AND HEART ADAPTATIONS TO PHYSICAL TRAINING AND SUPPLEMENTATION WITH AMINO ACIDS by DOROFEYEVA, ELENA E., DOROFEYEV, ANDREY E.

“…This study evaluated the role of amino acids supplementation on the heartʼs adaptation under extensive training conditions. Sixty active athletes (bicyclists…”
Get full text

Modified-Release Phosphatidylcholine (LT-02) for Ulcerative Colitis: Two Double-Blind, Randomized, Placebo-Controlled Trials by Dignass, Axel, Stremmel, Wolfgang, Horyński, Marek, Poyda, Oleksandr, Armerding, Peter, Fellermann, Klaus, Langhorst, Jost, Kuehbacher, Tanja, Uebel, Peter, Stein, Juergen, Novacek, Gottfried, Avalueva, Elena, Oliinyk, Oleksandr, Hasselblatt, Peter, Dorofeyev, Andrey, Heinemann, Heidrun, Mueller, Ralph, Greinwald, Roland, Reinisch, Walter

“…The aim of this study was to evaluate the efficacy of LT-02, a novel modified-release phosphatidylcholine (PC) formulation, for induction and maintenance of…”
Get full text

Gastrointestinal health: changes of intestinal mucosa and microbiota in patients with ulcerative colitis and irritable bowel syndrome from PM 2.5 -polluted regions of Ukraine by Dorofeyev, Andrey, Dorofeyeva, Anna, Borysov, Arsenii, Tolstanova, Ganna, Borisova, Tatiana

“…Here, clinical studies of patients were conducted to assess changes in patients with ulcerative colitis (UC) and irritable bowel syndrome (IBS) associated with…”
Get full text

The Combined Treatment of the Colorectal Cancer Associated with Ulcerative Colitis and Crohn'S Disease by Borota, Oleksandr, Polunin, German, Dorofeyev, Andrey, Sedakov, Igor, Borota, Oleksandr

Get full text

1079 - New Treatment Options for Proctitis. A Prospective, Double Blind, Randomized Study of Budesonide Suppositories by Kruis, Wolfgang, Neshta, Viacheslav, Pesegova, Marina, Alexeeva, Olga, Andreev, Pavel, Datsenko, Oleksii, Levchenko, Olena, Abdulkhakov, Sayar, Lozynskyy, Yuriy, Mostovoy, Yuriy, Soloviev, Konstatin, Dorofeyev, Andrey, Mohrbacher, Ralf, Greinwald, Roland, Siegmund, Britta

Get full text

New Treatment Options for Proctitis. A Prospective, Double Blind, Randomized Study of Budesonide Suppositories by Kruis, Wolfgang, Neshta, Viacheslav, Pesegova, Marina, Alexeeva, Olga, Andreev, Pavel, Datsenko, Oleksii, Levchenko, Olena, Abdulkhakov, Sayar, Lozynskyy, Yuriy, Mostovoy, Yuriy, Soloviev, Konstatin, Dorofeyev, Andrey, Mohrbacher, Ralf, Greinwald, Roland, Siegmund, Britta

Get full text

Efficacy and safety of a novel high-dose mesalazine tablet in mild to moderate active ulcerative colitis: a double-blind, multicentre, randomised trial by Dignass, Axel, Schnabel, Robert, Romatowski, Jacek, Pavlenko, Vladimir, Dorofeyev, Andrey, Derova, Jelena, Jonaitis, Laimas, Dilger, Karin, Nacak, Tanju, Greinwald, Roland

“…Background Adherence to mesalazine treatment is essential for the successful treatment of ulcerative colitis. Objective The objective of this study was to…”
Get full text

248 - Phase III Randomized, Double-Blind, Controlled Trial to Compare Biosimilar Infliximab (CT-P13) with Innovator Infliximab (INX) in Patients with Active Crohn's Disease: Early Efficacy and Safety Results by Ho Kim, Young, Ye, Byong Duk, Pesegova, Marina, Alexeeva, Olga, Osipenko, Marina, Lahat, Adi, Dorofeyev, Andrey, Salamon, Agnes, Fishman, Sigal, Levchenko, Olena, Cheon, Jae Hee, Scribano, Maria L., Mateescu, Radu-Bogdan, Lee, Kang-Moon, Eun, Chang Soo, Lee, Sang Joon, Lee, Sung Young

Get full text

Phase III Randomized, Double-Blind, Controlled Trial to Compare Biosimilar Infliximab (CT-P13) with Innovator Infliximab (INX) in Patients with Active Crohn's Disease: Early Efficacy and Safety Results by Ho Kim, Young, Ye, Byong Duk, Pesegova, Marina, Alexeeva, Olga, Osipenko, Marina, Lahat, Adi, Dorofeyev, Andrey, Salamon, Agnes, Fishman, Sigal, Levchenko, Olena, Cheon, Jae Hee, Scribano, Maria L, Mateescu, Radu-Bogdan, Lee, Kang-Moon, Eun, Chang Soo, Lee, Sang Joon, Lee, Sung Young

Get full text